Prevent Biometrics® Acquires Assets of X2 Biosystems, Consolidating Leadership in Head Impact Monitoring
Prevent Biometrics, the Cleveland Clinic spinoff that developed the first accurate, real-time system for monitoring head impacts in contact sports, today announced that it has acquired the head impact monitoring assets of Seattle-based X2 Biosystems. The transaction brings together the two leading head impact monitoring technologies, Prevent’s Impact Monitor Mouthguard, and X2’s skin patch-based platform.
Cleveland Clinic spinoff develops mouthguard that accesses concussion effects
The atmosphere inside the boxing gym was humid and reeked of sweat. Antonio Nieves, a former Cleveland Golden Gloves champion bantamweight, adjusted his digital mouthguard as he waited for his sparring match to start.
ClearFlow Announces Additional Positive US Clinical Trial Results at the 2018 NTI Critical Care Exposition
ClearFlow, Inc., a medical device company based in Anaheim, California, has announced that positive clinical trial results were presented at the National Teaching Institute (NTI) & Critical Care Exposition 2018 annual meeting on May 23rd, 2018 in Boston, MA. The findings were presented by the study principal investigator, Dr. Yvon Baribeau, of Catholic Medical Center in Manchester, New Hampshire, in a presentation titled “Active Clearance of Chest Drains Reduces Pleural Effusions and ICU Resources in patients undergoing Cardiac Surgery.”
Cleveland Clinic spinoff is at the center of efforts to remake the operating room
Centerline Biomedical, a Cleveland Clinic spinoff, is part of this Wall Street Journal story about tech advances that are making the operating room "smarter, more effective — and a lot less risky for patients."
Merchavia Reports Positive Results in a Breakthrough Trial for Early Prostate Cancer Diagnosis
Merchavia Holdings and Investments (TASE: MRHL), an Israeli investment company specializing in early-stage life science sector companies, reports positive results from a successful trial which was conducted Cleveland Clinic, a leading medical center, using IsoPSA, a test developed by CDx (in which Merchavia holds about 8%). As part of comprehensive medical research, conducted in several US centers, it was found that a simple blood test, based on technology developed by CDx can diagnose prostate cancer and avoid a large number of biopsies to diagnose prostate cancer. The research results confirm the results obtained in previous trials that were conducted.
NaviGate Cardiac Structures Inc. (“NCSI”) reports “excellent valvular function” at 1-year follow-up of first patient to receive GATE™ tricuspid valved stent via transjugular access
NaviGate Cardiac Structures Inc. (“NCSI”) announced today that the first patient to receive its replacement tricuspid valved stent via transjugular access has reached one-year post-procedure with excellent valvular function. This patient, along with 15 others treated to date under compassionate use protocols for severe tricuspid regurgitation, have received NCSI’s GATE™ tricuspid valved stent designed to lead to restored valvular function and improved quality of life.
Assay May Help Avoid Needless Prostate Biopsies
An assay that identifies abnormal PSA proteins showed promise as an aid to avoid unnecessary prostate biopsies triggered by worrisome PSA test results, according to data reported here.
ClearFlow Reports: ERAS Cardiac Surgery Recommends Active Tube Clearance Methodology in Consensus Statement Presented at the 98th Annual Meeting of The American Association for Thoracic Surgeons
ClearFlow Inc. has announced that an international society of leading heart surgeons known as ERAS® Cardiac Surgery presented evidenced-based expert consensus statements at the 98th annual meeting of the American Association for Thoracic Surgeons on April 28, 2018. Amongst key recommendations to promote enhanced patient outcomes after cardiac surgery is the use of Active Clearance techniques to maintain chest tube patency. The PleuraFlow® ACT® System is the only FDA cleared device with the indication to prevent or minimize retained blood in patients recovering from heart surgery.
Pulsante® Therapy Awarded Prestigious Forfait Innovation Package to Fast-Track Medical Innovation for Cluster Headache in France
Autonomic Technologies, Inc., today announced that the College of the French National Authority for Health (HAS) issued a favorable opinion on a Forfait Innovation package for the Pulsante® SPG Microstimulator System. The award will support a randomized controlled trial for patients suffering from cluster headache. Autonomic Technologies is a medical device company focused on the development and commercialization of innovative therapies for the treatment of severe headache.
This Smart Mouthguard Can Monitor Concussions
If you watched the Super Bowl LII earlier this month, you'll recall a moment in the second quarter when Patriots quarterback Tom Brady found Brandin Cooks wide open for a beautiful, 23-yard completion. But when Cooks turned to run for the end zone, he didn’t see Eagles safety Malcolm Jenkins gunning for him on the left. Like Jaws, Jenkins roared out of the murky deep, and leveled Cooks with a vicious hit to the head.